These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23292282)

  • 1. Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer.
    Muscat GE; Eriksson NA; Byth K; Loi S; Graham D; Jindal S; Davis MJ; Clyne C; Funder JW; Simpson ER; Ragan MA; Kuczek E; Fuller PJ; Tilley WD; Leedman PJ; Clarke CL
    Mol Endocrinol; 2013 Feb; 27(2):350-65. PubMed ID: 23292282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer prognosis predicted by nuclear receptor-coregulator networks.
    Doan TB; Eriksson NA; Graham D; Funder JW; Simpson ER; Kuczek ES; Clyne C; Leedman PJ; Tilley WD; Fuller PJ; Muscat GE; Clarke CL
    Mol Oncol; 2014 Jul; 8(5):998-1013. PubMed ID: 24785096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
    Ansems M; Hontelez S; Looman MW; Karthaus N; Bult P; Bonenkamp JJ; Jansen JH; Sweep FC; Span PN; Adema GJ
    J Natl Cancer Inst; 2010 Jan; 102(1):54-68. PubMed ID: 20008677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
    Wang Y; Gong X; Zhang Y
    Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34406386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer.
    Lin ML; Patel H; Remenyi J; Banerji CR; Lai CF; Periyasamy M; Lombardo Y; Busonero C; Ottaviani S; Passey A; Quinlan PR; Purdie CA; Jordan LB; Thompson AM; Finn RS; Rueda OM; Caldas C; Gil J; Coombes RC; Fuller-Pace FV; Teschendorff AE; Buluwela L; Ali S
    Oncotarget; 2015 Aug; 6(25):21685-703. PubMed ID: 26280373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct nuclear receptor expression in stroma adjacent to breast tumors.
    Knower KC; Chand AL; Eriksson N; Takagi K; Miki Y; Sasano H; Visvader JE; Lindeman GJ; Funder JW; Fuller PJ; Simpson ER; Tilley WD; Leedman PJ; Graham J; Muscat GE; Clarke CL; Clyne CD
    Breast Cancer Res Treat; 2013 Nov; 142(1):211-23. PubMed ID: 24122391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
    Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
    Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy.
    Bieche I; Parfait B; Le Doussal V; Olivi M; Rio MC; Lidereau R; Vidaud M
    Cancer Res; 2001 Feb; 61(4):1652-8. PubMed ID: 11245479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor.
    Suzuki T; Miki Y; Moriya T; Shimada N; Ishida T; Hirakawa H; Ohuchi N; Sasano H
    Cancer Res; 2004 Jul; 64(13):4670-6. PubMed ID: 15231680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
    Liu R; Guo CX; Zhou HH
    Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer.
    Jeong Y; Xie Y; Xiao G; Behrens C; Girard L; Wistuba II; Minna JD; Mangelsdorf DJ
    PLoS Med; 2010 Dec; 7(12):e1000378. PubMed ID: 21179495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications.
    Badve S; Collins NR; Bhat-Nakshatri P; Turbin D; Leung S; Thorat M; Dunn SE; Geistlinger TR; Carroll JS; Brown M; Bose S; Teitell MA; Nakshatri H
    Am J Pathol; 2010 May; 176(5):2139-49. PubMed ID: 20228224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
    Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
    [No Abstract]   [Full Text] [Related]  

  • 15. A Novel Prognostic Signature of mRNA-lncRNA in Breast Cancer.
    Liu Q; Wang Z; Kong X; Wang X; Qi Y; Gao R; Fang Y; Wang J
    DNA Cell Biol; 2020 Apr; 39(4):671-682. PubMed ID: 32040341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
    Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
    Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
    Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
    Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of nucleolin as a COUP-TFII coactivator of retinoic acid receptor β transcription in breast cancer cells.
    Litchfield LM; Riggs KA; Hockenberry AM; Oliver LD; Barnhart KG; Cai J; Pierce WM; Ivanova MM; Bates PJ; Appana SN; Datta S; Kulesza P; McBryan J; Young LS; Klinge CM
    PLoS One; 2012; 7(5):e38278. PubMed ID: 22693611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
    Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
    Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer.
    Reimer T; Koczan D; Müller H; Friese K; Thiesen HJ; Gerber B
    Breast Cancer Res; 2002; 4(5):R9. PubMed ID: 12223126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.